

May 13, 2022

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Sub: Scheme of Amalgamation

Ref: Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In furtherance to Company's letters dated February 3, 2020 and February 11, 2020 and in terms of Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that Hon'ble National Company Law Tribunal ("NCLT"), New Delhi Bench-III has, vide its order dated May 13, 2022, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ("The transferee Company") and APL Institute of Clinical Laboratory & Research Private Limited ("The transferor Company"), a wholly owned subsidiary of the transferee Company. The said sanction, however, is subject to the approval of scheme by NCLT, Ahmedabad also.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra

Company Secretary and Legal Head

